Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Agios Pharmaceuticals (AGIO) Change in Taxes (2024 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Taxes for 6 consecutive years, with -$683000.0 as the latest value for Q2 2025.

For Q2 2025, Change in Taxes changed N/A year-over-year to -$683000.0; the TTM value through Mar 2026 reached -$683000.0, down 200.0%, while the annual FY2025 figure was -$871000.0, 200.0% down from the prior year.
Change in Taxes hit -$683000.0 in Q2 2025 for Agios Pharmaceuticals, down from -$188000.0 in the prior quarter.
Across five years, Change in Taxes topped out at $52.7 million in Q3 2024 and bottomed at -$51.8 million in Q4 2024.